KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial. PMID 41629265 · Signal Transduct Target Ther · 2026-Feb-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol. PMID 41628935 · BMJ Open · 2026-Feb-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial. PMID 41266255 · J Nucl Med · 2026-Feb-02 The study is a human oncology Phase 3 randomized trial with original results. However, it is ineligible because the intervention is a diagnostic/imaging procedure (PSMA-targeted PET/MRI-guided biopsy) with no drug-containing therapeutic intervention, and the primary outcomes are diagnostic accuracy metrics (sensitivity, specificity, PPV, NPV) rather than time-to-event efficacy endpoints.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of oncologic safety and clinical effectiveness of immediate autologous fat grafting in breast-conserving surgery: a multicenter, prospective, randomized controlled clinical trial for breast cancer. PMID 41731868 · Int J Surg · 2026-Feb-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT). PMID 41621028 · Qual Life Res · 2026-Feb-01 The record describes a methodological sub-study embedded within the Phase 3 MOTION trial. It does not present the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) of the trial. The analysis focuses on defining responder thresholds for non-time-to-event clinical outcome assessments.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancer. PMID 41620988 · Qual Life Res · 2026-Feb-01 The record is a formal result of a randomized trial (KEYNOTE-590) with a drug intervention and a primary/key secondary time-to-event endpoint (OS, PFS). However, the specific analysis reported is a secondary, pre-specified health-related quality of life (Q-TWiST) analysis, which is not a primary efficacy endpoint per the eligibility criteria. The publication type 'Randomized Controlled Trial' does not confirm Phase III/IIIb or Phase II/III status, but the trial is a large, definitive randomized study. The analysis itself is a secondary endpoint analysis focused on quality of life, making it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Intrathecal Morphine for Enhanced Recovery After Laparoscopic Colorectal Surgery: A Randomized Clinical Trial. PMID 41433024 · JAMA Surg · 2026-Feb-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials. PMID 41343184 · JAMA Otolaryngol Head Neck Surg · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. PMID 41189315 · Neuro Oncol · 2026-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Elective versus involved target volume definition of stereotactic spine radiosurgery for spinal metastases: A phase II randomized clinical trial. PMID 41143555 · Neuro Oncol · 2026-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial. PMID 40876576 · Int J Radiat Oncol Biol Phys · 2026-Feb-01 The trial meets criteria for oncology, human, randomized, and phase 3, and reports primary results. However, it is ineligible because the intervention is a non-drug hydrogel, and the primary endpoint is a dosimetric measure, not a time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing Precutting Endoscopic Mucosal Resection Using Snare-Tip and Endoscopic Submucosal Dissection Knife for Large Nonpedunculated Colorectal Polyps: A Randomized Controlled Trial. PMID 40367489 · Am J Gastroenterol · 2026-Feb-01 The record is excluded because it does not meet the 'drug intervention' and 'time_to_event' criteria. The study compares procedural techniques (snare-tip vs. ESD knife) for endoscopic resection of colorectal polyps, which is a non-drug intervention. The primary efficacy endpoint (en bloc resection rate) is not a time-to-event outcome. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ligation site of the inferior mesenteric vein in laparoscopic radical resection of rectal cancer: a study protocol for a multicenter randomized-controlled trial. PMID 42147431 · Gastroenterol Rep (Oxf) · 2026-Feb 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial. PMID 41883885 · Cureus · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers. PMID 41853582 · Res Pract Thromb Haemost · 2026-Feb This is a retrospective cohort study (non-randomized) of direct oral anticoagulants in pediatric oncology patients. While it is oncology, human, and reports original results on a drug intervention, it lacks the required randomized controlled trial design (Phase III/IIIb or II/III) and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The primary endpoints are safety (bleeding) and efficacy (recurrent thrombosis), which are event rates, not time-to-event outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review. PMID 41822639 · Cureus · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Interim analysis of short-term outcomes between robotic and laparoscopic surgery for colon cancer: results from the ESSIMIC trial. PMID 41802309 · Ann Coloproctol · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Evaluating the Effect of Acceptance and Commitment Therapy on Post-traumatic Growth in Cancer Survivors: A Pilot Non-randomized Controlled Trial in a Greek Sample. PMID 41798432 · Cureus · 2026-Feb The study is a non-randomized, pilot trial of a psychotherapy intervention for cancer survivors. It does not meet the core criteria of being a randomized trial of a drug intervention with a time-to-event primary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ethical considerations in randomization for neurosurgical oncology trials: A scoping review. PMID 41798128 · Neurooncol Pract · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intravenous lidocaine for gastrointestinal recovery after colorectal surgery: the ALLEGRO placebo-controlled randomised trial and cost-effectiveness analysis. PMID 41731962 · Health Technol Assess · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Interim Results from a Randomized Trial. PMID 41726013 · Indian J Surg Oncol · 2026-Feb The trial is oncology, human, randomized, and includes a drug intervention, but it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis. The primary outcome is pCR, and distant metastasis is reported as a count, not a time-to-event. Phase is not definitively established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Audiovisual Education on Breast Cancer Screening and Fear Among Illiterate Women: A Double-Blind Randomised Controlled Trial. PMID 41709589 · J Eval Clin Pract · 2026-Feb Study is a randomized trial on breast cancer screening education, which is oncology-related and in humans. However, it lacks a drug intervention (the intervention is audiovisual education) and does not report a time-to-event efficacy endpoint. Therefore, it does not meet the core criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of two remote exercise programs on cardiorespiratory fitness, cardiac function, and vascular health in patients with breast cancer. PMID 41704018 · Physiol Rep · 2026-Feb The study is an oncology RCT in humans reporting original primary results, but it is excluded because: 1) The intervention is exercise-only (no drug-containing intervention), and 2) The endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any analysis involving Kaplan-Meier or HR). The endpoints measured are physiological (VO2peak, biomarkers).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Disparities in Distress Symptoms Among Cancer Inpatients, Outpatients and Relatives Through Introducing and Evaluating Digital Distress Screening. PMID 41689782 · Psychooncology · 2026-Feb The study is a randomized controlled trial in oncology patients, but it evaluates digital screening tools for distress, not a drug intervention. It does not have a Phase III/IIIb or Phase II/III designation. The primary endpoints are distress levels, usability, and acceptance, not time-to-event efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The clinical and cost-effectiveness of paravertebral blockade versus thoracic epidural blockade in reducing chronic post-thoracotomy pain: TOPIC2 RCT synopsis. PMID 41664616 · Health Technol Assess · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan. PMID 41660367 · EClinicalMedicine · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. PMID 41651641 · Lancet Haematol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial. PMID 41650746 · ESMO Open · 2026-Feb The study is an oncology, human, original result with drug intervention and time-to-event endpoints, but it is a single-arm phase II trial (as indicated by the text 'first prospective trial' and the small sample size of 57 patients). It is not randomized and not a Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). PMID 41640231 · Future Oncol · 2026-Feb The record is a plain language summary, not a formal results report. The abstract is empty, providing no data on the trial phase, human subjects, time-to-event endpoints, or original result details. The title indicates a randomized study (keyword: 'randomized controlled trial') with a drug intervention, but without a results abstract or full publication, eligibility criteria cannot be established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Gastric Cancer Mortality-to-Incidence Ratios in Latin America and the Caribbean: A Machine Learning Analysis of Socioeconomic and Clinical Research Predictors. PMID 41637677 · JCO Glob Oncol · 2026-Feb This is a retrospective, country-level epidemiological and research landscape analysis, not a report of a randomized clinical trial with time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SNF-CLIMEDIN: A Randomized Trial of Digital Support and Intervention in Patients With Advanced Non-Small Cell Lung Cancer. A Hellenic Cooperative Oncology Group Study. PMID 41632937 · JCO Clin Cancer Inform · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of preoperative inspiratory muscle training combined with education course on postoperative pulmonary complications in high-risk patients with lung cancer after video-assisted thoracoscopic surgery: a randomized controlled trial. PMID 41626065 · Contemp Clin Trials Commun · 2026-Feb The record is an oncology randomized controlled trial with original results (interim analysis), but it fails three key eligibility criteria: 1) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the interim futility stopping suggests it is not a definitive phase trial. 2) The primary endpoint is postoperative pulmonary complications (a binary, non-time-to-event outcome), not a time-to-event efficacy endpoint like OS, PFS, etc. 3) The intervention is non-drug (inspiratory muscle training and education), not a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study). PMID 41624484 · JHEP Rep · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cartilage organoids bridging bench to bedside: A steroid-free strategy for early osteoarthritis repair. PMID 41560786 · Mater Today Bio · 2026-Feb The record does not meet the fundamental eligibility criterion of being an oncology study. It is a trial for osteoarthritis, not a human malignant neoplasm. Therefore, it is excluded regardless of other criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women. PMID 41560336 · Clin Transl Sci · 2026-Feb The record describes a pharmacokinetic/bioavailability study in healthy volunteers, not a Phase III/IIIb or Phase II/III randomized efficacy trial with a time-to-event endpoint in cancer patients.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. PMID 41548565 · Lancet Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sevoflurane's inhibitory effect on postoperative colorectal cancer cell proliferation. PMID 41546564 · Pak J Pharm Sci · 2026-Feb The record meets criteria for oncology, human subjects, and randomization, but fails on phase (not Phase III/IIIb or definitive Phase II/III), primary endpoint (no time-to-event efficacy endpoint), and drug intervention (anesthetic, not oncology drug). The report is an original result but for a non-eligible study type.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in patients with refractory oral lichen planus: A multicenter, pragmatic, randomized controlled trial. PMID 41539096 · Phytomedicine · 2026-Feb 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib. PMID 41534416 · Breast · 2026-Feb Study is randomized and reports a time-to-event endpoint (TTD) for a drug (abemaciclib) in oncology. However, the primary endpoint is adherence persistence (PR24), and the study's intervention is patient coaching, not a drug itself. The report does not explicitly confirm Phase III/IIIb or Phase II/III status, which is required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers. PMID 41529317 · Clin Oncol (R Coll Radiol) · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat. PMID 41526614 · Leukemia · 2026-Feb The record describes a subgroup/biomarker analysis of a Phase 3 randomized trial. While the study is oncologic, human, randomized, and drug-interventional, the reported endpoint (RBC-TI duration, clonal burden) is not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis as required by the adjudication criteria. Therefore, it is not eligible for the KM digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Chewing gum versus heat therapy for postoperative recovery in patients undergoing gynecologic oncology surgery: A randomized controlled trial. PMID 41518771 · Eur J Oncol Nurs · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sentinel node mapping with carbon nanoparticles versus lymphadenectomy in early cervical cancer. PMID 41512771 · Int J Gynecol Cancer · 2026-Feb The trial is a randomized oncology study with a time-to-event efficacy endpoint, but it does not meet the required drug intervention criterion. The intervention is a surgical technique and a diagnostic mapping agent (carbon nanoparticles), which is not considered a systemic drug therapy for the purposes of this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials. PMID 41500083 · Lung Cancer · 2026-Feb The record is a biomarker analysis (subgroup) from two randomized trials (OAK and POPLAR). While the underlying trials are likely Phase III, the phase is not explicitly established in the provided metadata. More critically, this is not the original formal result report of a Phase III/IIIb or Phase II/III trial; it is a secondary, exploratory, or post-hoc analysis focusing on biomarker prognostication and predictive value. The original primary or key secondary time-to-event efficacy endpoint report (e.g., OS, PFS) for the drug intervention (atezolizumab vs. chemotherapy) is not the subject of this paper.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial. PMID 41496424 · Breast · 2026-Feb The abstract describes a biomarker (HER2/CEP17 ratio) analysis from the parent Phase III NeoALTTO trial, which is a sub-study focusing on predictive value for pCR and EFS. While the parent trial is eligible, this specific report is a pre-planned subgroup/biomarker analysis, not the primary or definitive report of the trial's main efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Post-operative pain after laparoscopy in gynecologic surgery: randomized trial on peritoneal gas drainage. PMID 41485402 · Int J Gynecol Cancer · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial. PMID 41478264 · Oral Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Iodine125 grain isotope detection compared to standard metal guide detection for breast cancers: The IODINE BREAST, a randomised, non-inferiority trial. PMID 41477927 · Eur J Surg Oncol · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Pesco-Vegetarian Food Components Promote Colonocyte Ferroptosis in Preclinical Mouse Models and a Randomized Crossover Trial in Healthy Human Adults. PMID 41461276 · J Nutr · 2026-Feb The study is an original randomized controlled trial, but it fails multiple key eligibility criteria: it is not a Phase III or Phase II/III trial, the intervention is not a drug (it is a dietary supplement), and the outcome is not a time-to-event efficacy endpoint. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
MARGIN: Randomized Trial of Arterial CT Portography Versus Standard Imaging Guidance for Percutaneous Thermal Ablation of Colorectal Liver Metastases. PMID 41457158 · Cardiovasc Intervent Radiol · 2026-Feb This is a protocol manuscript for a randomized trial. The primary endpoint is complete ablation at 3 months (a radiological response measure), not a time-to-event endpoint like OS, PFS, etc. The intervention is procedural (imaging guidance for ablation), not a drug-containing intervention. The phase is not explicitly stated as Phase III or II/III. As a protocol without results, it does not meet the eligibility criteria for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -